Nasdaq IPOs

Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised $252 million by offering 14 million shares at $18, above the upwardly revised range of $16 to $17. The company offered 1 million more shares than anticipated. It originally pla

Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised $252 million by offering 14 million shares at $18, above the upwardly revised range of $16 to $17. The company offered 1 million more shares than anticipated. It originally pla

Inventiva, a Phase 2 French biotech developing therapies for NASH and other diseases, raised $108 million by offering 7.5 million ADSs at $14.40, the midpoint of the revised range of $13.40 to $15.40. The company originally planned to offer the same number of ADSs at the as-conve

Inventiva, a Phase 2 French biotech developing therapies for NASH and other diseases, raised $108 million by offering 7.5 million ADSs at $14.40, the midpoint of the revised range of $13.40 to $15.40. The company originally planned to offer the same number of ADSs at the as-conve

Vision Marine Technologies, a Canadian manufacturer of electric powerboats and outboard powertrain systems, filed on Thursday with the SEC to raise up to $18 million in an initial public offering. The company generates most of its revenue from sales of its electric powe

Vital Farms, the largest US producer of pasture-raised eggs and butter, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. From its beginning on a 27-acre plot of land in Texas, Vital Farms now has a network of 200 family farms and has becom

Trean Insurance Group, a specialty casualty insurer in the US focused on workers' compensation, announced terms for its IPO on Thursday. The Wayzata, MN-based company plans to raise $150 million by offering 10.7 million shares (33% insider) at a price range of $13 to $15. At the

Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised the proposed deal size for its upcoming IPO on Thursday. The South San Francisco, CA-based company now plans to raise $215 million by offering 13 million shares at a price rang

Poseida Therapeutics, a phase 2 biotech developing CAR T cell therapies for multiple myeloma, raised the proposed deal size for its upcoming IPO on Thursday. The San Diego, CA-based company now plans to raise $224 million by offering 14 million shares at a price range of $16 to $

Relay Therapeutics, a Phase 1 biotech developing small molecule therapies for solid tumors, announced terms for its IPO on Thursday. The Cambridge, MA-based company plans to raise $250 million by offering 14.7 million shares at a price range of $16 to $18. At the midpoint of the

Inventiva, a Phase 2 French biotech developing therapies for NASH and other diseases, raised the proposed range for its upcoming IPO on Wednesday. The Daix, France-based company now plans to raise $108 million by offering 7.5 million shares at a price range of $13.40 to $15.40. T

In the second quarter of 2020, 38 IPOs raised $15.1 billion, mostly in June as the market bounced back amid soaring IPO returns. The slow start to the quarter caused activity to decline from the 2Q19, when 62 IPOs raised $25.1 billion, boosted by Uber and other unicorns. Hea

GoHealth, a medicare-focused health insurance marketplace, announced terms for its IPO on Wednesday. The Chicago, IL-based company plans to raise $751 million by offering 39.5 million shares at a price range of $18 to $20. At the midpoint of the proposed range, GoHealth would com

Therapeutics Acquisition, a blank check company formed by RA Capital targeting the biotech industry, raised $118 million by offering 11.8 million shares at $10. The company had previously planned to raise $100 million by offering 10.0 million shares. When it first filed in June,

BlueCity Holdings, a leading online LGBTQ community and dating platform in China, raised $85 million by offering 5.3 million ADSs at $16, within the range of $15 to $17. Co-founder and CEO Ma Baoli indicated on $5 million of the IPO. At pricing, the company commands a fully

2020's blank check boom hit another major milestone with Therapeutics Acquisition (TXAC). For the first time in their roughly 20-year history, a SPAC has completed an IPO by selling common shares rather than units, signaling ever-greater demand in the space. SPAC offerings

Rocket Companies, a leading mortgage lender operating under the Rocket and Quicken brands, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. However, this is likely a placeholder for a deal we estimate could raise up to $3 billion. Rocket Co

Launching an IPO in the middle of a global pandemic, when unemployment in the U.S. is at its highest level since the 1930s and GDP has fallen dramatically, seems like a crazy idea. Yet Vroom did just that.

2020's blank check boom has hit another major milestone with Therapeutics Acquisition (TXAC). For the first time ever, a SPAC has completed an IPO by selling common shares to investors. SPAC offerings normally include units consisting of shares of common stock and tradable w

ACE Convergence Acquisition, a blank check company formed by ACE Equity Partners and industry veterans targeting a tech business, filed on Monday with the SEC to raise up to $200 million in an initial public offering. The Wilmington, DE-based company plans to raise $200 million b